Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CERS

CERS - Cerus Corp Stock Price, Fair Value and News

$2.36-0.13 (-5.22%)
Market Closed

25/100

CERS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

25/100

CERS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.99

Target 3M

$2.28

Target 6M

$2.12

CERS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CERS Price Action

Last 7 days

-6.7%

Last 30 days

14.6%

Last 90 days

68.6%

Trailing 12 Months

11.3%

CERS RSI Chart

CERS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CERS Valuation

Market Cap

453.3M

Price/Earnings (Trailing)

-28.38

Price/Sales (Trailing)

1.35

EV/EBITDA

-30.6

Price/Free Cashflow

2.7K

CERS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.99

Target 3M

$2.28

Target 6M

$2.12

CERS Fundamentals

CERS Revenue

Revenue (TTM)

201.3M

CERS Earnings

Earnings (TTM)

-16.0M

Earnings Growth (Yr)

99.35%

Earnings Growth (Qtr)

99.67%

CERS Profitability

EBT Margin

-7.78%

Return on Equity

-25.99%

Return on Assets

-7.42%

Free Cashflow Yield

0.04%

CERS Investor Care

Shares Dilution (1Y)

3.43%

Diluted EPS (TTM)

-0.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024190.4M194.1M197.7M201.3M
2023187.9M187.6M187.2M186.8M
2022000188.3M
2021116.2M120.6M126.5M159.5M
202095.0M96.7M98.9M114.2M
2019076.3M79.0M135.9M
201850.1M48.3M44.8M79.7M
201736.6M36.8M37.5M43.6M
201634.2M34.6M36.7M37.2M
201536.2M36.5M34.2M34.2M
201437.8M36.2M36.1M36.4M
201337.7M38.7M41.0M39.7M
201233.1M35.6M36.1M36.7M
201122.1M23.0M25.7M30.6M
2010019.2M20.4M21.7M
200900018.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Cerus Corp

CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
 CEO
 WEBSITEcerus.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES665

Cerus Corp Frequently Asked Questions

CERS is the stock ticker symbol of Cerus Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Cerus Corp is 453.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CERS's fair value in chart for subscribers.

The fair value guage provides a quick view whether CERS is over valued or under valued. Whether Cerus Corp is cheap or expensive depends on the assumptions which impact Cerus Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CERS.

As of Wed Jan 28 2026, CERS's PE ratio (Price to Earnings) is -28.38 and Price to Sales (PS) ratio is 1.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CERS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Cerus Corp has provided -0.08 (multiply by 100 for percentage) rate of return.